E
Aptevo Therapeutics Inc. APVO
$1.50 $0.106.92% NASDAQ
Recommendation
Prev Close
$1.40
Volume
1,316,650
Avg Vol (90D)
4,054,193
Market Cap
$4.60M
Dividend & Yield
--
52-Week Range
$1.32 - $298.00
P/E (TTM)
--
EPS (TTM)
-$608.93
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter
10/8/2025 - ACCESS Newswire
Aptevo Therapeutics files to sell 6.9M shares of common stock for holders
10/1/2025 - TipRanks Financial Blog
Aptevo Therapeutics files to sell 6.9M shares of common stock for holders
10/1/2025 - The Fly
Biotech Stocks To Watch Now - September 18th
9/18/2025 - MarketBeat
Why Is Aptevo Therapeutics Stock (APVO) Up 85% Today?
9/18/2025 - TipRanks Financial Blog
Aptevo Therapeutics (NASDAQ:APVO) Rating Increased to Strong-Buy at Roth Capital
9/18/2025 - Ticker Report
Aptevo Therapeutics Surges Over 46% After Hours On Breakthrough AML Treatment Results
9/18/2025 - Benzinga
Biotech Stocks To Add to Your Watchlist - September 16th
9/17/2025 - MarketBeat
Aptevo Announces 100% Remission in AML Trial
9/16/2025 - TipRanks Financial Blog
Aptevo Therapeutics Stock Rallies On 100% Remission Rate In Acute Myeloid Leukemia Trial Cohort
9/16/2025 - Stocktwits News Feed
Market movers: Webtoon Entertainment, Hershey, Rocket Lab, Aptevo Therapeutics
9/16/2025 - Proactive Investors - UK
Aptevo Therapeutics shares spike on promising trial results for leukemia therapy
9/16/2025 - Proactive Investors - UK
Aptevo Therapeutics (APVO) Shows Promising Results in AML Treatment Trial
9/16/2025 - GuruFocus
Aptevo says mipletamig deliver 100% remission rate in RAINIER cohort 3
9/16/2025 - TipRanks Financial Blog
Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML
9/16/2025 - ACCESS Newswire
Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update
9/16/2025 - Ticker Report
Aptevo Therapeutics Expands Anti-Cancer Pipeline with Patents
9/4/2025 - TipRanks Financial Blog
Aptevo Therapeutics expands anti-cancer pipeline with APVO452, APVO451
9/4/2025 - The Fly
Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules
9/4/2025 - ACCESS Newswire
Reviewing Revelation MIS (OTCMKTS:WOWU) & Aptevo Therapeutics (NASDAQ:APVO)
9/2/2025 - Ticker Report
Wall Street Zen Upgrades Aptevo Therapeutics (NASDAQ:APVO) to Hold
8/19/2025 - Ticker Report
Aptevo Therapeutics highlights APVO442 preclinical candidate for prostate cancer
8/13/2025 - TipRanks Financial Blog
Aptevo Therapeutics highlights APVO442 preclinical candidate for prostate cancer
8/13/2025 - The Fly
Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer
8/13/2025 - ACCESS Newswire
Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update
8/11/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$24.04M
EBIT (TTM)
-$24.30M
Net Income (TTM)
-$24.03M
Balance Sheet
Total Assets (Q)
$15.62M
Total Debt (Q)
$4.21M
Total Liabilities (Q)
$9.10M
Book Value Per Share (Q)
$2.02
Cash Flow
Cash from Operations (TTM)
-$24.65M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$25.99M
Net Change in Cash (TTM)
$1.34M
Filings
Filing Date
Monday, August 11, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 3 and 7 (est)
Price History
Loading...
Beta
-1.18
7-Day Total Return
-0.67%
30-Day Total Return
-14.78%
60-Day Total Return
-29.91%
90-Day Total Return
-53.71%
Year to Date Total Return
-98.36%
1-Year Total Return
-99.25%
2-Year Total Return
-99.98%
3-Year Total Return
-100.00%
5-Year Total Return
-100.00%
52-week Low
Sep 17, 2025 - $1.32
52-week High
Dec 12, 2024 - $298.00
Valuation
Market Cap
$4.60M - Nano Cap
Enterprise Value
-$597.92K
Price/Sales (TTM)
--
Price/Book (Q)
0.69
Dividends and Shares
Shares Outstanding
0.74
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
aptevotherapeutics.com
Phone Number
206 838 0500
Address
2401 4th Avenue
Seattle, WA 98121
Country
United States
Year Founded
2016
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the... more
NASDAQ 10/31/2025 2:06PM Eastern Quotes delayed